Title:Agile 3+ and Metabolic Dysfunction-Associated Fatty Liver Disease:
Detecting Advanced Fibrosis based on Reported Liver Stiffness
Measurement in FibroScan and Laboratory Findings
Volume: 3
Author(s): Mohammadjavad Sotoudeheian*
Affiliation:
- Physiology Research Center, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
Keywords:
Area under curve, assessment, transient elastography, accuracy, noninvasive tools, liver cirrhosis, elasticity imaging techniques.
Abstract: Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD), formerly known as
Non-alcoholic fatty liver disease (NAFLD), is characterized by fat accumulation in the liver and
is associated with obesity, insulin resistance, and metabolic syndrome. Early detection and intervention
are crucial to prevent disease progression to advanced fibrosis, cirrhosis, and liver failure.
Non-invasive tests like transient elastography (TE), the Fibrosis-4 (FIB-4) index, the Enhanced
Liver Fibrosis (ELF) score, and magnetic resonance imaging (MRI) are safer and more convenient
than invasive procedures like liver biopsy for detecting advanced fibrosis in MAFLD patients.
Agile 3+ is a non-invasive test that combines liver stiffness measurement (LSM) with clinical and
laboratory findings to detect advanced fibrosis in MAFLD patients. It has shown high accuracy
in detecting advanced fibrosis in MAFLD patients. The combination of LSM and laboratory findings
provides a more accurate assessment of disease severity, making Agile 3+ a reliable, noninvasive
test for assessing liver fibrosis in MAFLD patients. In summary, MAFLD is a common
condition that can progress to advanced fibrosis and liver failure if left untreated. Non-invasive
tests such as Agile 3+ have emerged as valuable tools for detecting advanced fibrosis in MAFLD
patients, providing a more accurate assessment of disease severity and making it a reliable noninvasive
test for assessing liver fibrosis in MAFLD patients.
